Marie Bosslett, Assistant Editor

Almirall's sarecycline gains NMPA approval in China, offering a new oral treatment for moderate-to-severe acne, enhancing patient access and outcomes.

The new therapy targets age-related hair loss with a unique formula, promoting thicker, healthier hair for men over 50.

Patient education and partner involvement significantly enhance melanoma detection, especially in underserved and skin-of-color populations, improving survival outcomes.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

Explore top dermatology conferences and meetings in February 2026 and let us know which ones you'll be attending!

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on the FDA's breakthrough designation of litifilimab for CLE, data on bitopertin in EPP treatment, the role of icotrokinra in the psoriasis landscape, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Icotrokinra emerges as a groundbreaking oral treatment for moderate-to-severe psoriasis, showing superior efficacy compared to existing therapies at Maui Derm 2026.

Jennelle Daly, PA-C, explores the integration of aesthetic dermatology and wellness, emphasizing holistic approaches for optimal skin health and patient outcomes.

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.

Galderma's Bill Andriopoulos, PhD, discusses Dysport's real-world success and evolving trends in aesthetic injectables, emphasizing patient satisfaction and innovative treatments.

Discover insights from Bill Andriopoulos, PhD, on Relfydess, a groundbreaking neuromodulator utilizing PEARL Technology for enhanced efficacy and safety.

Explore the importance of high-energy visible (HEV) blue light protection, especially post procedures, and discover effective patient strategies for managing melasma and skin health.

This review of the latest vitiligo studies includes insights on the efficacy of ritlecitinib, the risk of herpes zoster, oxidative stress in red blood cells for this patient population, and more.

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Jennelle Daly, MPAS, PA-C, reveals essential winter sunscreen insights, emphasizing UVA risks and patient education for effective photoprotection against melanoma.

Obagi and Alpha Aesthetics Partners will collaborate on the ALOHA Program, enhancing real-world evidence for the innovative saypha MagIQ hyaluronic acid filler.

Christopher Bunick, MD, PhD, led a vital discussion on innovative vitiligo treatments, emphasizing combination therapies and psychosocial support for effective management.

Discover how a new topical cream effectively improves skin volume and elasticity in patients experiencing rapid weight loss.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on phase 3 delgocitinib in lichen sclerosus, amlitelimab's every-12-week dosing in AD, Galderma's phase 3 aesthetics data, and more.

Galderma showcased relabotulinumtoxinA and abobotulinumtoxinA at TOXINS 2026, highlighting innovative injectables with sustained results and high patient satisfaction.

The survey revealed significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of January.

Atopia Therapeutics advances ATP-R13 as a promising oral therapy for atopic dermatitis (AD), showing significant efficacy and enhanced patent protection.

New research uncovers significant knowledge gaps among Chinese patients with acne regarding oral medications, highlighting the need for improved education strategies.

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.